Neurocrine Biosciences (NBIX) Revenue Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | 2.22% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 4.22% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | -0.31% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 9.51% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -1.40% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 28.43% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 8.98% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Alkermes | 8.17 Bn | 7.51 Bn | 397.90 Mn | -7.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.43% |
| Mar 31, 2026 | 24.66% |
| Dec 31, 2025 | 25.04% |
| Sep 30, 2025 | 27.02% |
| Jun 30, 2025 | 225.15% |
| Mar 31, 2025 | 22.62% |
| Dec 31, 2024 | 26.24% |
| Sep 30, 2024 | 28.09% |
| Jun 30, 2024 | 26.89% |
| Mar 31, 2024 | 29.62% |
| Dec 31, 2023 | 27.61% |
| Sep 30, 2023 | 24.50% |
| Jun 30, 2023 | 14.40% |
| Mar 31, 2023 | 21.03% |
| Dec 31, 2022 | 19.06% |
| Sep 30, 2022 | 20.43% |
| Jun 30, 2022 | -52.23% |
| Mar 31, 2022 | 30.92% |
| Dec 31, 2021 | 33.38% |
| Sep 30, 2021 | 24.94% |